Search For "gilead sciences"
Dr Reddy's Labs in licensing pact with Gilead Sciences for Remdesivir
Updated : 5 years, 11 months ago IST
Hyderabad (Telangana) [India], June 13 (ANI): Dr Reddy's Laboratories said on Saturday it has entered into a non-exclusive licensing agreement with Gilead Sciences Inc that will grant Dr Reddy's the right to register, manufacture and sell Gilead's investigational drug Remdesivir, a potent
Read More
Zydus signs licensing agreement with Gilead to manufacture and market Remd
Updated : 5 years, 11 months ago IST
Ahmedabad (Gujarat) [India], June 13 (ANI): Healthcare major Zydus Cadila has signed a non-exclusive licensing agreement with Gilead Sciences Inc for the manufacturing and distribution of Remdesivir, the investigational drug which has been issued an emergency use authorisation by the US Food
Read More
'US' current supply of Remdesivir to get exhausted by end of June'
Updated : 5 years, 11 months ago IST
Washington DC [USA], June 8 (ANI): The US government's current supply of Remdesivir, the only drug till now known to be working against coronavirus, will exhaust by the end of June.
Read More
COVID-19: Remdesivir gets nod from CDCSO for 'restricted emergency use' on
Updated : 5 years, 11 months ago IST
New Delhi [India], June 2 (ANI): In a significant development, the country's top drug controller the Central Drug Control Standard Organisation (CDCSO) has given permission to Gilead Sciences for marketing authorization of its anti-viral drug Remdesivir "only for restricted emergency use" o
Read More
Jubilant Life Sciences surges 5 pc after signing deal with Gilead for prod
Updated : 6 years ago IST
Mumbai (Maharashtra) [India], May 13 (ANI): The share price of Jubilant Life Sciences surged 5 per cent hitting upper circuit of Rs 429.95 per share on Wednesday after the company signed a deal with US-based Gilead Sciences Inc for production of Remdesivir to fight COVID-19.
Read More
COVID-19: Cipla enters into licensing pact with Gilead to manufacture and
Updated : 6 years ago IST
Mumbai (Maharashtra) [India], May 13 (ANI): Pharmaceutical major Cipla said on Wednesday it has signed a non-exclusive licensing agreement with Gilead Sciences Inc for manufacturing and distributing investigational medicine Remdesivir which has been issued an emergency use authorisation by t
Read More
Gilead in talks with Indian drugmakers to produce remdesivir for treatment
Updated : 6 years ago IST
New Delhi [India], May 6 (ANI): US-based biopharmaceutical major Gilead Sciences said on Wednesday it is negotiating long-term voluntary licences with several generic drugmakers in India to produce remdesivir for developing countries.
Read More
India can easily do synthesis of antiviral drug - Remdesivir: Former ICMR
Updated : 6 years ago IST
New Delhi [India], May 3 (ANI): India can easily do the synthesis of antiviral drug - Remdesivir - if allowed by the US-based pharma major Gilead Sciences, said Dr Nirmal K Ganguly, former Director-General, Indian Council of Medical Research (ICMR), on Saturday.
Read More
Antiviral drug -- Remdesivir -- is next big thing in fight against COVID-1
Updated : 6 years ago IST
New Delhi [India], May 2 (ANI): Since the onset of global coronavirus pandemic, scientists, experts and medical practitioners are vigorously engaged in researching for the most effective treatment of COVID-19 patients. As per the experts, antiviral drug -- Remdesivir -- could be the answe
Read More
Gilead's anti-viral remdesivir gets FDA emergency use authorisation for tr
Updated : 6 years ago IST
California [USA], May 2 (ANI): US-based biopharmaceutical major Gilead Sciences said that the US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for investigational anti-viral remdesivir to treat COVID-19.
Read More
Tata Trusts, Gilead sign MoU on viral hepatitis in India
Updated : 8 years, 9 months ago IST
New Delhi, Aug 8 (ANI): Tata Trusts has announced signing of an agreement with the US-headquartered biopharmaceutical company Gilead Sciences to explore collaboration to tackle the viral hepatitis in the country, a release stated.
Read More
Tata Trusts, Gilead sign MoU to address viral hepatitis in India
Updated : 8 years, 9 months ago IST
New Delhi, Aug 4 (ANI): Tata Trusts and Gilead Sciences, Inc. today signed a Memorandum of Understanding (MoU) under the presence of Chairman Tata Trusts, Ratan Tata to explore collaborating within India on an initiative to address the burden of viral hepatitis in the country.
Read More